Deep-pocketed investors have adopted a bearish approach towards AbbVie (NYSE:ABBV), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ABBV usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for AbbVie. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 25% leaning bullish and 62% bearish. Among these notable options, 2 are puts, totaling $90,428, and 6 are calls, amounting to $250,885.
Expected Price Movements
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $135.0 and $165.0 for AbbVie, spanning the last three months.
Analyzing Volume & Open Interest
In today's trading context, the average open interest for options of AbbVie stands at 243.17, with a total volume reaching 1,616.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in AbbVie, situated within the strike price corridor from $135.0 to $165.0, throughout the last 30 days.
AbbVie Option Activity Analysis: Last 30 Days
Significant Options Trades Detected:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|
ABBV | CALL | SWEEP | BULLISH | 09/20/24 | $15.1 | $15.05 | $15.1 | $150.00 | $75.5K | 286 | 202 |
ABBV | PUT | SWEEP | BEARISH | 11/15/24 | $3.5 | $3.4 | $3.5 | $145.00 | $52.1K | 496 | 32 |
ABBV | CALL | SWEEP | NEUTRAL | 06/28/24 | $2.33 | $2.27 | $2.29 | $165.00 | $44.1K | 19 | 703 |
ABBV | PUT | SWEEP | BEARISH | 11/15/24 | $4.45 | $4.3 | $4.45 | $150.00 | $38.2K | 208 | 86 |
ABBV | CALL | TRADE | BEARISH | 11/15/24 | $7.45 | $7.3 | $7.35 | $165.00 | $36.7K | 335 | 54 |
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
In light of the recent options history for AbbVie, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Present Market Standing of AbbVie
- With a volume of 1,513,498, the price of ABBV is down -0.94% at $159.76.
- RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
- Next earnings are expected to be released in 72 days.
What The Experts Say On AbbVie
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $183.5.
- Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on AbbVie with a target price of $180.
- Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on AbbVie with a target price of $187.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
财力雄厚的投资者对艾伯维(纽约证券交易所代码:ABBV)采取了看跌的态度,这是市场参与者不容忽视的。我们对本辛加公开期权记录的追踪今天揭示了这一重大举措。这些投资者的身份仍然未知,但是ABBV的如此重大变动通常表明即将发生重大事件。
我们今天从观察中收集了这些信息,当时Benzinga的期权扫描仪重点介绍了AbbVie的8项非同寻常的期权活动。这种活动水平与众不同。
这些重量级投资者的总体情绪存在分歧,25%的人倾向于看涨,62%的人倾向于看跌。在这些值得注意的期权中,有两个是看跌期权,总额为90,428美元,6个是看涨期权,总额为250,885美元。
预期的价格走势
在评估了交易量和未平仓合约之后,很明显,主要市场走势者将注意力集中在AbbVie在过去三个月的135.0美元至165.0美元之间的价格区间上。
分析交易量和未平仓合约
在当今的交易背景下,艾伯维期权的平均未平仓合约为243.17,总交易量达到1,616.00。随附的图表描绘了过去30天AbbVie高价值交易的看涨期权和看跌期权交易量以及未平仓合约的变化,行使价走势从135.0美元到165.0美元不等。
AbbVie 期权活动分析:过去 30 天
检测到的重要期权交易:
符号 | 看跌/看涨 | 交易类型 | 情绪 | Exp。日期 | 问 | 出价 | 价格 | 行使价 | 总交易价格 | 未平仓合约 | 音量 |
---|
ABBV | CALL | SWEEP | 看涨 | 09/20/24 | 15.1 美元 | 15.05 美元 | 15.1 美元 | 150.00 美元 | 75.5 万美元 | 286 | 202 |
ABBV | PUT | SWEEP | 看跌 | 11/15/24 | 3.5 美元 | 3.4 美元 | 3.5 美元 | 145.00 美元 | 52.1 万美元 | 496 | 32 |
ABBV | CALL | SWEEP | 中立 | 06/28/24 | 2.33 美元 | 2.27 美元 | 2.29 美元 | 165.00 美元 | 44.1 万美元 | 19 | 703 |
ABBV | PUT | SWEEP | 看跌 | 11/15/24 | 4.45 美元 | 4.3 美元 | 4.45 美元 | 150.00 美元 | 38.2 万美元 | 208 | 86 |
ABBV | CALL | TRADE | 看跌 | 11/15/24 | 7.45 美元 | 7.3 美元 | 7.35 美元 | 165.00 美元 | 36.7 万美元 | 335 | 54 |
关于 AbbVie
艾伯维是一家制药公司,在免疫学(与Humira、Skyrizi和Rinvoq合作)和肿瘤学(与Imbruvica和Venclexta合作)方面有着丰富的经验。该公司于2013年初从雅培分拆出来。2020年对Allergan的收购增加了几种美容领域的新产品和药物(包括肉毒杆菌毒素)。
鉴于AbbVie最近的期权历史,现在应该将重点放在公司本身上。我们的目标是探索其目前的表现。
艾伯维目前的市场地位
ABBV的价格下跌了0.94%,至159.76美元,交易量为1,513,498美元。
RSI 指标暗示,标的股票目前在超买和超卖之间保持中立。
下一份财报预计将在72天后公布。
专家对艾伯维的看法
在过去的一个月中,两位行业分析师分享了他们对该股的见解,提出平均目标价为183.5美元。
与仅交易股票相比,期权是一种风险更高的资产,但它们具有更高的获利潜力。严肃的期权交易者通过每天自我教育、扩大交易规模、关注多个指标以及密切关注市场来管理这种风险。